Citigroup
MDGL icon

Citigroup’s Madrigal Pharmaceuticals MDGL Stock Holding History

Citigroup’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.67M Sell
18,000
-12,000
-40% -$6.15M ﹤0.01% 1647
2026
Q1 		$15.7M Buy
30,000
+7,500
+33% +$3.58M 0.01% 1206
2025
Q4 		$13.1M Sell
22,500
-4,500
-17% -$2.3M 0.01% 1357
2025
Q3 		$12.4M Buy
27,000
+500
+2% +$187K 0.01% 1347
2025
Q2 		$8.02M Sell
26,500
-13,500
-34% -$4.02M ﹤0.01% 1534
2025
Q1 		$13.2M Buy
40,000
+27,200
+213% +$8.94M 0.01% 1193
2024
Q4 		$3.95M Sell
12,800
-5,300
-29% -$1.49M ﹤0.01% 2197
2024
Q3 		$3.84M Buy
18,100
+2,000
+12% +$512K ﹤0.01% 2074
2024
Q2 		$4.51M Buy
+16,100
New +$3.83M ﹤0.01% 1704
2022
Q3 		– Sell
-17,900
Closed -$1.28M – 6125
2022
Q2 		$1.28M Buy
+17,900
New +$1.32M ﹤0.01% 2425

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup's MDGL Position: Q2 2026 in Review

Citigroup increased its Madrigal Pharmaceuticals (MDGL) stake by 46% in Q2 2026, buying an estimated $5.98M and bringing the position to 37,255 shares worth $20M. The position accounts for 0.01% of the portfolio, ranked #1172.

Citigroup first reported a position in MDGL in Q2 2013 and has held it in 49 quarters since. The position peaked at $30.3M in Q4 2024. 415 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Citigroup held 37,255 shares of Madrigal Pharmaceuticals worth $20M as of Q2 2026.
  • Citigroup bought 11,666 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $5.98M.
  • Madrigal Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q2 2026, its #1172 holding.
  • Citigroup first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • Citigroup's Madrigal Pharmaceuticals position peaked at $30.3M in Q4 2024.
  • 415 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.